Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1458-1465

  Altaner, Cestmir ^a,b   Altanerova, Veronika ^b   Cihova, Marina ^a   Ondicova, Katarina ^c   Rychly, Boris ^d   Baciak, Ladislav ^e   Mravec, Boris ^c,f  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Center for Cell Therapy and Regenerative Medicine   (Slovakia)

^c Physics and Informatics   (Slovakia)

^d Cytopathos Ltd   (Slovakia)

^e SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

^f INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

5 fluorocytosine; CDy::UPRT; glioblastoma; suicide gene therapy; therapeutic stem cells

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; PRODRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER REGRESSION; CANCER SURGERY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INOCULATION; KAPLAN MEIER METHOD; MALE; MESENCHYMAL STEM CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SUICIDE GENE THERAPY; SURVIVAL TIME;

EID: 84891828863     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28455     Document Type: Article

References (32)

1. Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25: 4127-36.
2. Charles N, Holland EC,. The perivascular niche microenvironment in brain tumor progression. Cell Cycle 2010; 9: 3012-21.
3. Altaner C,. Glioma cancer stem cells and their role in therapy. Atlas Genet Cytogenet Oncol Haematol 2012; 16: 757-64.
4. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004; 96: 1593-603.
5. Kucerova L, Altanerova V, Matuskova M, et al. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res 2007; 67: 6304-13.
6. Cavarretta IT, Altanerova V, Matuskova M, et al. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther 2010; 18: 223-31.
7. Alieva M, Bagõ JR, Aguilar E, et al. Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response. PloS One 2012; 7: e35148.
8. Altanerova V, Cihova M, Babic M, et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 2012; 130: 2455-63.
9. Altaner C,. Prodrug cancer gene therapy. Review. Cancer Lett 2008; 270: 191-201.
10. Aboody KS, Najbauer J, Danks MK,. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008; 15: 739-52.
11. Zhao LR, Duan WM, Reyes M, et al. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002; 174: 11-20.
12. Le Blanc K,. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003; 5: 485-9.
13. Koppula PR, Chelluri LK, Polisett N, et al. Histocompatibility testing of cultivated human bone marrow stromal cells-a promising step towards pre-clinical screening for allogeneic stem cell therapy. Cell Immunol 2009; 259: 61-5.
14. Griffin MD, Ritter T, Mahon BP,. Immunological aspects of allogeneic mesenchymal stem cell therapies. Hum Gene Ther 2010; 21: 1641-55.
15. Kondo T, Setoguchi T, Taga T,. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101: 781-6.
16. Zheng X, Shen G, Yang X, et al. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2002; 67: 3691-7.
17. Halász B, Pupp L,. Hormone secretion of the anterior pituitary gland after physical interruption of all nervous pathways to the hypophysiotrophic area. Endocrinology 1965; 77: 553-62.
18. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 603-8.
19. Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 2010; 290: 58-67.
20. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97: 12846-51.
21. Bourbeau D, Lavoie G, Nalbantoglu J, et al. Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status. J Gene Med 2004; 6: 1320-32.
22. Bourbeau D, Lau CJ, Jaime J, et al. Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus. Cancer Res 2007; 67: 3387-95.
23. Paxinos G, Watson C,. The rat brain in stereotaxic coordinates. New York: Academic Press. 1997; 256.
24. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-22.
25. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000; 60: 6649-55.
26. Cihova M, Altanerova V, Altaner C,. Stem cell based cancer gene therapy. Mol Pharm 2011; 8: 1480-7.
27. Bexell D, Gunnarsson S, Tormin A, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 2009; 17: 183-190.
28. Bexell D, Scheding S, Bengzon J,. Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther 2010; 18: 1067-75.
29. Seong M, Kim JSW, Chang HJ, et al. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res 2012; 72; 4807-17.
30. Choi SA, Hwang SK, Wang KC, et al. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma. Neuro Oncol 2010; 13: 61-9.
31. Lee DH, Ahn Y, Kim SU, et al. Targeting rat brain stem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 2009; 15: 4925-34.
32. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01172964?term=5- fluorocytosine%2C+cytosine+deaminase&rank=1